Current management of diabetic tractional retinal detachments
- PMID: 30451175
- PMCID: PMC6256889
- DOI: 10.4103/ijo.IJO_1217_18
Current management of diabetic tractional retinal detachments
Abstract
Twenty-five percent of diabetes-related vision loss stems from complications of proliferative diabetic retinopathy (PDR). Panretinal photocoagulation has been the preferred treatment of high-risk PDR for decades and more recently intravitreal injections of drugs that inhibit the actions of vascular endothelial growth factor have become popular. But despite these treatments PDR may progress uncontrollably to advanced pathologies such as traction retinal detachments (TRDs), combined traction/rhegmatogenous retinal detachments (TRD/RRDs), vitreous hemorrhages, rubeosis iridis, and traction maculopathies, which produce mild-to-severe loss of vision. TDR have long been the most common indication for PDR-related vitreoretinal surgery. Vitrectomy surgery is indicated for recent (<6 months duration) TRD involving the macula, progressive TRD that threatens the macula, and recent data suggest that chronic macula-involving TRDs (>6 months duration) may also benefit. Combined TRD/RRD represents a particularly challenging surgical condition but advances in surgical instrumentation, dissection techniques, and post-operative tamponade have produced excellent success rates. The recent development of small-gauge vitrectomy systems has persuaded most surgeons to switch platforms since these appear to produce shorter surgical times and quicker post-operative recoveries. Pre-operative injections of bevacizumab are frequently administered for persistent neovascularization to facilitate surgical dissection of pre-retinal fibrosis and reduce the incidence of post-operative hemorrhages. Recent trends toward earlier surgical intervention and expanded indications are likely to continue as surgical instrumentation and techniques are further developed.
Keywords: Diabetes; diabetic retinopathy; tractional retinal detachment; vitrectomy.
Conflict of interest statement
There are no conflicts of interest
Figures








Similar articles
-
Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.Ophthalmology. 2009 May;116(5):927-38. doi: 10.1016/j.ophtha.2008.11.005. Epub 2009 Mar 9. Ophthalmology. 2009. PMID: 19269033
-
Surgical management of retinal diseases: proliferative diabetic retinopathy and traction retinal detachment.Dev Ophthalmol. 2014;54:196-203. doi: 10.1159/000360467. Epub 2014 Aug 26. Dev Ophthalmol. 2014. PMID: 25196770 Review.
-
Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment.Medicine (Baltimore). 2016 Feb;95(8):e2731. doi: 10.1097/MD.0000000000002731. Medicine (Baltimore). 2016. PMID: 26937902 Free PMC article.
-
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials.Retina. 2020 Jun;40(6):1021-1028. doi: 10.1097/IAE.0000000000002633. Retina. 2020. PMID: 31567817 Free PMC article.
-
Management of proliferative diabetic retinopathy.Compr Ophthalmol Update. 2007 Sep-Oct;8(5):245-56. Compr Ophthalmol Update. 2007. PMID: 18201511 Review.
Cited by
-
Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment.Aging (Albany NY). 2020 Dec 29;12(24):24504-24521. doi: 10.18632/aging.202453. Epub 2020 Dec 29. Aging (Albany NY). 2020. PMID: 33373320 Free PMC article.
-
YAP is essential for TGF-β-induced retinal fibrosis in diabetic rats via promoting the fibrogenic activity of Müller cells.J Cell Mol Med. 2020 Nov;24(21):12390-12400. doi: 10.1111/jcmm.15739. Epub 2020 Sep 20. J Cell Mol Med. 2020. PMID: 32951332 Free PMC article.
-
Diabetic Disease of the Eye in Canada: Consensus Statements from a Retina Specialist Working Group.Ophthalmol Ther. 2024 May;13(5):1071-1102. doi: 10.1007/s40123-024-00923-0. Epub 2024 Mar 23. Ophthalmol Ther. 2024. PMID: 38526804 Free PMC article.
-
Vitrectomy for diabetic retinopathy: A review of indications, techniques, outcomes, and complications.Taiwan J Ophthalmol. 2024 Jan 31;14(4):519-530. doi: 10.4103/tjo.TJO-D-23-00108. eCollection 2024 Oct-Dec. Taiwan J Ophthalmol. 2024. PMID: 39803397 Free PMC article. Review.
-
Clinical features and surgical outcomes of complications of proliferative diabetic retinopathy in young adults with type 1 diabetes mellitus versus type 2 diabetes mellitus - A comparative observational study.Indian J Ophthalmol. 2021 Nov;69(11):3289-3295. doi: 10.4103/ijo.IJO_1293_21. Indian J Ophthalmol. 2021. PMID: 34708790 Free PMC article.
References
-
- Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–63. - PubMed
-
- Centers for Disease Control and Prevention. Blindness caused by diabetes – massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep. 1996;45:937–41. - PubMed
-
- Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103:1796–806. - PubMed
-
- Boyer DS, Yoon YH, Belfort R, Jr, Bandello F, Maturi RK, Augustin AJ. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical